A Randomized, Open-label, Single Dose, 3x3 Partial Replicated Crossover Study to Evaluate the Pharmacokinetics and Safety/Tolerability Between a Fixed Dose Combination of Fimasartan 120mg/Atorvastatin 40mg and Co-administration of Fimasartan 120mg and Atorvastatin 40mg in Healthy Male Volunteers.
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Atorvastatin/fimasartan (Primary) ; Atorvastatin; Fimasartan
- Indications Hypercholesterolaemia; Hypertension
- Focus Pharmacokinetics
- Sponsors Boryung Pharmaceutical
- 09 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
- 25 Jan 2017 Status changed from not yet recruiting to recruiting.
- 19 Dec 2016 New trial record